Kiniksa Pharmaceuticals International (KNSA) EBIT Margin (2021 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted EBIT Margin of 13.66% for Q1 2026, up 39.66% on a QoQ basis from 9.78% in Q4 2025, and up 403.0% year-over-year from 2.72% in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) EBIT Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's EBIT Margin history runs 6 years deep, the most recent figure standing at 13.66% for Q1 2026.
- Quarterly EBIT Margin rose 403.0% year-over-year to 13.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.36% (up 1565.0% YoY) and the FY2025 annual result came in at 11.4%, up 2217.0% from the prior year.
- EBIT Margin was 13.66% for Q1 2026 at Kiniksa Pharmaceuticals International, up from 9.78% in the prior quarter.
- Across five years, EBIT Margin topped out at 46.82% in Q3 2022 and bottomed at 72.44% in Q1 2022.
- A 5-year average of 7.72% and a median of 4.08% in 2022 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin soared 45461 bps — and 2023, when it sank 6312 bps.
- Kiniksa Pharmaceuticals International's EBIT Margin stood at 4.08% in 2022, then jumped by 102 bps to 0.1% in 2023, then sank by 16315 bps to 15.75% in 2024, then soared by 162 bps to 9.78% in 2025, then surged by 40 bps to 13.66% in 2026.
- Business Quant data shows KNSA's EBIT Margin at 13.66% in Q1 2026, 9.78% in Q4 2025, and 13.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 13.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.66% |
| Dec 31, 2025 | 9.78% |
| Sep 30, 2025 | 13.28% |
| Jun 30, 2025 | 12.86% |
| Mar 31, 2025 | 9.63% |
| Dec 31, 2024 | -15.75% |
| Sep 30, 2024 | -8.61% |
| Jun 30, 2024 | -0.11% |
| Mar 31, 2024 | -20.71% |
| Dec 31, 2023 | 0.10% |
| Sep 30, 2023 | -16.30% |
| Jun 30, 2023 | -4.41% |
| Mar 31, 2023 | -23.16% |
| Dec 31, 2022 | -4.08% |
| Sep 30, 2022 | 46.82% |
| Jun 30, 2022 | -71.81% |
| Mar 31, 2022 | -72.44% |
| Dec 31, 2021 | -192.75% |
| Sep 30, 2021 | -253.55% |
| Jun 30, 2021 | -526.41% |